TCL Archive Marker Research Plans Described; NCAB May Consider Asking For Special Study Section For Those Grants March 11, 1983
TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive Unorthodox Panel Considers NIH Mandated Role In Study of Unconventional Medical Practices June 26, 1992
